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aBstraCt
BaCkground: The aim of this study is to analyze the numbers and the economic burden of intravitreal anti-VEGF 
agents and intravitreal dexamethasone (IVD) implants administered to patients with diabetic retinopathy (DR), 
age-related macular degeneration (AMD) and retinal vein occlusion (RVO).
Material and Methods: The retrospective case-control study included 1525 patients diagnosed with DME, 
neovascular AMD and RVO, and received intravitreal anti-VEGF and IVD between January 2016 and December 
2018. Intravitreal anti-VEGF administration was performed within the framework of the Pro Re Nata (PRN) re-
gimen. The prices of anti-VEGF agents and IVDs were calculated on the average of the prices in the relevant year.
results: The total number of intravitreal injections in 3 years was 5864. During the 3-year follow-up, on average, 
ranibizumab (Lucentis) was applied 3.56 ± 2.25 times, alfibercept (Eylea) was applied 3.31 ± 2.16 times, and IVD 
(Ozurdex) was applied 1.70 ± 0.83 times. The anti-VEGF numbers in 2016, 2017 and 2018 were 1997, 1801, 2066, 
respectively. In total, the 3-year drug cost was 3,587,812.44 USD.
ConClusions: The economic burden of intravitreal anti-VEGF and IVD treatment for retinal diseases is so im-
portant to developing countries such as Turkey. The economic burden created by anti-VEGF agents and IVDs in 
Turkey will reduce in a serious sense, and the legal concerns of physicians will decrease thanks to the decision taken 
by the Turkish Medicines and Medical Devices Agency (TMMDA).
keY words: retinal diseases; anti-VEGF; economic burden; diabetic retinopathy; age-related macular degeneration; 
retinal vein occlusion
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introduCtion
Diabetic retinopathy (DR), age-related macu-
lar degeneration (AMD) and retinal vein occlu-
sion (RVO) are the most important causes of 
vision loss [1]. It is estimated that these three 
retinal diseases will gradually increase all over the 
world [2]. Diabetic macular edema (DME) due to 
DR, neovascular AMD and RVO-induced macu-
lar edema (ME) are the main reasons for decreased 
vision. In recent years, intravitreal anti-vascular 
endothelial growth factor (anti-VEGF) agents 
have been used frequently in the treatment of 
ME due to these three retinal diseases [3–5]. The 
most commonly used anti-VEGF agents are af-
libercept (Eylea, Regeneron Pharmaceuticals, Tar-
rytown, New York, USA and Bayer Healthcare 
Pharmaceuticals, Berlin, Germany), bevacizumab 
(Avastin, Genentech, Inc., South San Francisco, 
CA, USA) and ranibizumab (Lucentis; Genen-
tech, South San Francisco, CA, USA). Intravitreal 
dexamethasone implant (IVD; Ozurdex; Allergan 
Inc, Irvine, CA, USA) is also used for treatment 
of ME. The efficiencies of all these agents were 
similar in the studies conducted [5–7]. 
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The widespread use of anti-VEGF agents causes 
a serious economic burden. In a study, it was re-
ported that 2.1 million anti-VEGFs were used in 
the United States in 2013 and the approximate 
cost of this amount was more than 2.3 billion dol-
lars [8]. Studies have shown that bevacizumab is 
30–40 times cheaper than other agents and it is 
cost-effective [9–11]. As in many countries, there 
is no indication for intraocular use of bevacizumab 
in Turkey. Legal and ethical problems related to 
this issue limit the use of bevacizumab by ophthal-
mologists. Turkish Medicines and Medical Devices 
Agency (TMMDA) took a new decision on De-
cember 28, 2018, and according to this decision, 
it is stated that 3 dose bevacizumab should be used 
in patients who need anti-VEGF, and then other 
anti-VEGF agents can be used only in resistant 
and/or unresponsive cases [12]. It is estimated that 
this application aims to reduce the economic bur-
den of anti-VEGF agents.
The aim of this study is to analyze the numbers 
and the economic burden of intravitreal anti-VEGF 
agents and IVD implants administered to patients 
with DME, AMD and RVO between January 
2016 and December 2018.
Material and Methods
This retrospective study included 1525 patients 
who were diagnosed with DME, neovascular AMD 
and RVO, and received intravitreal anti-VEGF 
between January 2016 and December 2018. The 
study was conducted in the Retina Clinic of Sakarya 
University Education and Research Hospital. Ap-
proval for the study was obtained from the local 
ethics committee (Sakarya University Medical Fac-
ulty Ethics Committee, 15.02.2019/38). A detailed 
ophthalmologic examination was performed in all 
patients who were referred to the ophthalmology 
clinic, referred to the retinal unit, and followed 
up. In all patients, the best corrected visual acuity 
with Snellen chart, intraocular pressure measure-
ment with Goldmann applanation tonometer, and 
anterior and posterior segment examination with 
a slit-lamp bio microscopy were performed. In ad-
dition, in all patients, a central foveal thickness 
with optical coherence tomography device (OCT, 
Cirrus HD OCT, Carl Zeiss Meditec, Dublin, CA, 
USA) and a fundus photograph and fluorescein 
angiography with fundus fluorescein angiography 
device (FFA, Canon Sales Co., Inc., Chiba, Japan) 
were performed. As a result of these measurements, 
intravitreal anti-VEGF treatment was applied to the 
patients in need of anti-VEGF by the ophthalmolo-
gist in the operating room conditions. Intravitreal 
anti-VEGF administration was performed within 
the framework of the PRN  protocol adopted in 
EURETINA guidelines [13]. According to this 
protocol, all naive patients were given monthly in-
jections in OCT until the intraretinal/subretinal 
fluid passed and anti-VEGF was administered when 
needed. In addition, anti-VEGF changes were per-
formed or dexamethasone implants were used in 
patients who did not respond to treatment. 
The prices of anti-VEGF agents and IVDs were 
calculated on the average of the prices in the rel-
evant year (the year anti-VEGF administered). 
The calculations made over Turkish Lira (TL) 
were converted to US dollar (USD) by basing on 
the average dollar exchange rate of the Central 
Bank of the Republic of Turkey in the relevant 
year. The average price of Lucentis in 2016, 2017, 
2018 was 704.16 USD (2128.97 TL), 644.58 USD 
(2352.72 TL), 505.75 USD (2437.83 TL), re-
spectively. In the same years, the price of Eylea 
was 592.54 USD (1791.5 TL), 496.45 USD 
(1812.05 TL) and 415.99 USD (2005.16 TL), 
respectively. Furthermore, the price of Ozurdex 
was 665.96 USD (2013.48 TL), 609.57 USD 
(2224.93 TL), 529.92 USD (2554.34 TL), respec-
tively. The decrease in drug prices in dollar terms be-
tween 2016 and 2018 is due to the depreciation of 
TL against USD. (USD / TL average rate was 3.02, 
3.65, and 4.82 in 2016, 2017, 2018, respectively.)
This study was conducted at the Department 
of Ophthalmology of Sakarya University Medical 
Education and Research Hospital. Prior approval 
from the Institutional Review Board was taken and 
written informed consent was obtained from each 
subject. The study was performed in adherence to 
the Declaration of Helsinki.
statistiCal analYsis
Data were analyzed using SPSS (version 17.0, 
SPSS Inc., Chicago, IL, USA) and Microsoft Excel 
(Microsoft Corp., Redmond, WA, USA). Descrip-
tive analysis was used to analyze the data and the 
numerical data were given as mean and standard 
deviation (SD). The Kolmogorov-Smirnov test was 
used for the analysis of the distribution of the nor-
mality, and while the parametric Student’s t-test was 
used for the analysis of the normally distributed 
parameters, non-parametric ANOVA test and Post 
Hoc Tests (Tamhane) were used to analyze abnor-
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mally distributed data. p < 0.05 was considered 
statistically significant.
results
In total, data of 1525 patients were ana-
lyzed: 742 (48.7%) of the patients were male 
and 783 (51.3%) were female. The mean age of 
the patients was 66.17 ± 10.36 years in males 
and 65.36 ± 9.95 years in females, and there was 
not a statistically significant difference between 
them (p = 0.118). 801 patients (52.5%) had 
DME, 395 (25.9%) had neovascular AMD, and 
329 (21.6%) had RVO. The total number of in-
travitreal anti-VEGFs in 3 years was 5864. The 
anti-VEGF numbers in 2016, 2017 and 2018 were 
1997, 1801, 2066, respectively (Tab. 1). In total, 
3-year drug cost was 3,587,812.44 USD, and the 
distribution of drugs by years and drug type is sum-
marized in Table 1. 
During the 3-year follow-up, on average annually, 
ranibizumab (Lucentis) was applied 3.56 ± 2.25 times 
(range 1–13), alfibercept (Eylea) was applied 
3.31 ± 2.16 times (1–19), and IVD (Ozurdex) was 
applied 1.70 ± 0.83 times (range 1–4) There was no 
significant difference between the number of ranibi-
zumab administered in DME and the number ap-
plied in AMD, but it was significantly higher than 
RVO. In addition, the average number of ranibizu-
mab applied in AMD was significantly higher than 
RVO (p = 0.249, p < 0.05, p = 0.045). There was no 
significant difference between the mean alfibercept 
number applied in DME and AMD, but DME was 
significantly higher than RVO. However, no signifi-
cant difference was found between the mean alfiber-
cept number applied in AMD and those applied in 
RVO (p = 0.858, p = 0.004, p = 0.069). Intravitreal 
dexamethasone implant was used in patients with 
DME and RVO, and its use was significantly higher 
in patients with DME than in patients with RVO 
(p < 0.05) (Tab. 2).
disCussion
Vision loss due to retinal diseases such as DME, 
AMD, and RVO is increasing day by day and these 
diseases are a major part of visual loss [14–16]. In-
travitreal anti-VEGF is one of the proven treatment 
modalities for reducing visual loss [17, 18]. How-
ever, the high cost of anti-VEGF agents and their 
frequent repetition constitute a serious economic 
burden [9]. In this study, we aimed to investigate 
the economic burden of intravitreal anti-VEGF and 
IVD treatment for DME, AMD and RVO. 
There are several studies analyzing the frequency 
and cost of anti-VEGF use in retinal diseases. In his 
study, Turpcu et al. compared the number and cost 
of intravitreal injections applied in DME, RVO and 
AMD. In AMD, an annual average of 5.6 times 
alfibercept and 5.3 times ranibizumab were per-
formed while 4.5 times aflibercept and 5 times 
ranibizumab were performed in RVO, and there 
was no significant difference in anti-VEGF usage 
numbers and prices. On average, 4.4 ± 2.9 times 
table 1. distribution and cost of intravitreal drugs by years
2016 (n) 2017 (n) 2018 (n) total (n) 2016 (usd) 2017 (usd) 2018 (usd) total (usd)
lucentis 1096 712 1056 2864 772,632.82 458,941.54 534,097.20 1,765,671.56 
eylea 901 1089 1010 3000 534,483.94 540,636.28 420,168.40 1,495,288.61 
ozurdex 121 150 292 563 80,672.54 91,435.47 154,744.20 326,852.27 
Total 1997 1801 2066 5864 1,387,789.30 1,091,013.31 1,109,009.80 3,587,812.44
table 2. Comparison of intravitreal agents in diabetic macular edema (dMe), age-related macular degeneration (aMd), 
retinal vein occlusion (rVo) diseases (average of 3 years)
dMe (Mean) aMd (Mean) rVo (Mean) total (Mean) p (dMe-aMd) p (dMe-rVo) p (aMd-rVo)
lucentis 
(n = 805)
3.79 ± 2.30 3.46 ± 2.303 2.91 ± 1.84 3.56 ± 2.25 0.249 < 0.05 0.045
eylea 
(n = 907)
3.46 ± 2.12 3.34 ± 2.31 2.90 ± 1.94 3.31 ± 2.16 0.858 < 0.05 0.069
ozurdex 
(n = 331)
1.80 ± 0.82 - 1.53 ± 0.82 1.70 ± 0.83 – < 0.05 –
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ranibizumab was administered to DME patients in 
a year. The annual cost of treatment with ranibizu-
mab in DME patients was lower than in RVO and 
AMD patients [11]. In our study, it was observed 
that the mean number of injections was lower and it 
is thought that this was due to long follow-up peri-
ods (3 years) and treatment protocol In their study, 
Johnson et al. found that the total direct health care 
cost per patient in patients treated with anti-VEGF 
was 14,725 euros in France, 10,927 euros in Spain 
and 9,647–13,759 pounds in the UK and 50–80% 
of this cost was the drug cost. They also reported 
that the most commonly used anti-VEGF agent was 
ranibizumab [19]. Drug prices in Turkey are cheap-
er than in Europe and anti-VEGF annual costs 
are significantly lower than the European coun-
tries. However, Turkey is a developing country and 
despite being cheaper in dollar, anti-VEGF agents 
are estimated to have a higher economic burden in 
the country.
In a study conducted by Hollingworth et al., the 
use of anti-VEGF agents (ranibizumab, bevacizu-
mab) in various retinal diseases in the UK has been 
found to increase by 215% over a 5-year period 
(2010/2011 to 2014/2015). In addition, it is esti-
mated that there will be a 447 million pounds drug 
spending during the 2015/2016 period due to the 
intravitreal use of anti-VEGF agents [20]. Moreo-
ver, these expenditures are expected to increase with 
each passing day. In a study by Dakin et al., it was 
reported that the replacement of ranibizumab treat-
ment for AMD patients with bevacizumab would 
save around 102 million pounds annually [21]. In 
another study, Hutton et al. reported that in the 
10-year period (2010–2020), approximately 18 bil-
lion dollars could be saved if all other anti-VEGF 
agents were replaced with bevacizumab [22]. In our 
study, it is seen that the number of patients with 
a sudden-VEGF need has increased over the years 
and the economic burden created by this situation 
also increases. We believe that the transition to be-
vacizumab will provide significant savings.
Bevacizumab is an anti-VEGF agent with prov-
en efficacy in retinal diseases such as DME, AMD, 
RVO, despite the lack of FDA approval for in-
travitreal use (indication in colon cancer) [6, 23, 
24]. In addition, the cost of the intravitreal use of 
bevacizumab is quite inexpensive compared to other 
drugs [25]. In addition, many studies have proven 
that bevacizumab is more cost-effective in various 
retinal diseases than other anti-VEGF agents on the 
market [10, 21, 26]. Turkish Medicines and Medi-
cal Devices Agency has confirmed the intravitreal 
use of bevacizumab since 2019 in Turkey. In light 
of this information, considering that there will be 
a significant increase in the use of bevacizumab 
from 2019 with the recent decision by TMMDA, 
we think that the economic burden created by an-
ti-VEGF drugs will significantly decrease. 
Legal and ethical issues are also important 
in anti-VEGF preferences of ophthalmolo-
gists. Hollingworth et al. reported that physicians 
had to choose expensive agents because of the lack 
of legal basis [20]. With the decision taken by 
the TMMDA, we think that the legal problems 
ophthalmologists in Turkey go through will re-
duce, and they may feel more comfortable in their 
anti-VEGF preferences. 
ConClusion
As a result, we think the financial burden created 
by anti-VEGF in Turkey will reduce in a serious 
sense, and the legal concerns of physicians will de-
crease thanks to the decision taken by the TMMDA. 
We intend to continue our current work in the fol-
lowing years. Thus, we will have the opportunity to 
evaluate the amount of money spent on anti-VEGF 
drugs and the savings provided. 
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